AzTrials
AzTrials

Ovarian CancerNCT07035067

Multidimensional Burden of Platinum Resistant Ovarian Cancer (PROC) on Patients and Caregivers in Canada

An observational study of Ovarian Cancer and Caregiver Burden, run by PeriPharm at 1 site in Canada.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

Filling the gap in Canadian evidence on the burden of PROC on QoL is essential. It will help better understand the impact of PROC on multiple aspects of the lives of patients and their caregivers and the real-life hurdles faced by PROC patients and their caregivers. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Ovarian Cancer, Caregiver Burden, Patient Burden
How many people
24 participants
Where
1 siteCanada
Study dates
15 Jul 2025to 1 Apr 2026
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: Patients with ovarian cancer and caregivers of patients with ovarian cancer who are part Ovarian Cancer Canada mailing list.

Patient Inclusion Criteria

  1. ≥18 years old
  2. Patients with PROC who received >1 prior line of therapy identified through a screening survey. PROC will be defined as recurrence less than 6 months after last platinum chemotherapy (i.e. carboplatin or cisplatin)
  3. Ability to read and understand French or English
  4. Signature of ICF

Patients Exclusion Criteria

  1. Patients with PSOC, defined as those who:
  2. Have not progressed within less than 6 months after completion of platinum-based chemotherapy or;
  3. Are still on platinum chemotherapy or;
  4. Receive maintenance therapy.
  5. Patients with platinum-refractory ovarian cancer, defined as not responding or disease progressing during therapy or within three months after the last dose

Caregivers Inclusion Criteria:

  1. ≥18 years old
  2. Current caregiver of a patient with PROC (see definition to be used above) who received >1 prior line of therapy identified through a screening survey.
  3. Ability to read and understand French or English
  4. Signature of ICF.

Caregivers Exclusion Criteria:

  1. Caregivers of patients with PSOC (see definition above)
  2. Caregivers of PROC patients who have passed away
  3. Caregivers of platinum-refractory patients (see definition above)

Trial locations and contacts

1 site in 1 country.

Canada1 site

  • PROxy Network, an initiative of PeriPharm Inc.

    Montreal, Quebec, H2Y 1V3

Other trials in Canada

About this study

Filling the gap in Canadian evidence on the burden of PROC on QoL is essential. It will help better understand the impact of PROC on multiple aspects of the lives of patients and their caregivers and the real-life hurdles faced by PROC patients and their caregivers. The outputs of this study will help better understand the hurdles and challenges they face and the significant unmet medical need.

Being tested
No intervention
Medical subject headings
Ovarian Neoplasms, Caregiver Burden

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • No interventionOther

    No specific intervention is assess in this study.

Study groups in NCT07035067
Study groupRoleWhat they receive
Patients with PROC part of Ovarian Cancer Canada mailing listsNot described
Receives: Other: No intervention
Caregiver of PROC patients part of Ovarian Cancer Canada mailing listsNot described
Receives: Other: No intervention

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. To estimate the quality of life of patient with ovarian cancer

    Using the the Functional Assessment of Cancer Therapy - Ovarian (FACT-O) and EuroQol 5-dimendion 5-level (EQ-5D-5L)

    Measured: At recruitment

Secondary outcomes (4)

  1. Patient's symptoms assessment

    Using the Measure of Ovarian Symptoms and Treatment (MOST-T24 (V2))

    Measured: At recruitment

  2. Caregiver's Quality of Life

    Using the CareGiver Oncology Quality of Life (CarGOQoL) questionnaire

    Measured: At recruitment

  3. Patients and caregivers work productivity loss and activity impairment

    Using the Work Productivity and Activity Impairment (WPAI) questionnaire

    Measured: At recruitment

  4. Patient's preference in treatment

    Using a questionnaire specifically developed for this study based on a literature search, physician input and patient association input.

    Measured: At recruitment

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Jun 2025
  2. Study start15 Jul 2025
  3. Primary completion1 Apr 2026
  4. Study completion1 Apr 2026

Why it stopped: Recruitment

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Cross-sectional
Enrolment
24 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07035067
Sponsor's protocol ID
Ovarian Cancer
Status last verified
Apr 2026
First submitted
4 Jun 2025
Last updated
7 Apr 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Ovarian Cancer and Caregiver Burden, run by PeriPharm at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 7 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was stopped early (reason given: Recruitment). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

To estimate the quality of life of patient with ovarian cancer (time frame: At recruitment). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07035067.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Apr 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in